Development of177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators

Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer

(2011) Ilse Vaneycken et al.   FASEB JOURNAL

Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties

(2011) H. Wallberg et al.   JOURNAL OF NUCLEAR MEDICINE

Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice

(2010) Lea Olive Tchouate Gainkam et al.   Contrast Media & Molecular Imaging

Synthesis and biodistribution studiesof 177Lu-trastuzumab as a therapeutic agent in the breast cancer mice model

(2010) Samira Rasaneh et al.   JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS

Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands

(2010) Marc Hens et al.   NUCLEAR MEDICINE AND BIOLOGY

HER-2 as a Target for Breast Cancer Therapy

(2009) M. Ignatiadis et al.   CLINICAL CANCER RESEARCH

Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours

(2009) Marleen Melis et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

HER2+ Breast Cancer

(2008) David G. Hicks et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Circumventing De Novo and Acquired Resistance to Trastuzumab: New Hope for the Care of ErbB2-Positive Breast Cancer

(2008) Martine Piccart   Clinical Breast Cancer

Imaging of HER-2 Overexpression in Tumors for Guiding Therapy

(2008) V. Tolmachev   CURRENT PHARMACEUTICAL DESIGN

Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

(2008) B. M. Tijink et al.   MOLECULAR CANCER THERAPEUTICS